Research Papers:

Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab

Man Xing, Xiang Wang, Yudan Chi and Dongming Zhou _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:28262-28272. https://doi.org/10.18632/oncotarget.8596

Metrics: PDF 1993 views  |   HTML 5090 views  |   ?  


Man Xing1, Xiang Wang1, Yudan Chi1, Dongming Zhou1

1Vaccine Research Center, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Science, Shanghai, China

Correspondence to:

Dongming Zhou, email: [email protected]

Keywords: EGFR, cetuximab, adenovirus, colorectal cancer, gene therapy

Received: December 24, 2015     Accepted: March 28, 2016     Published: April 5, 2016


Cetuximab is a chimeric monoclonal antibody, approved to treat patients with metastatic colorectal cancer (mCRC), head and neck squamous cell carcinoma (HNSCC), non-small-cell lung cancer (NSCLC) for years. It functions by blocking the epidermal growth factor receptor (EGFR) from receiving signals or interacting with other proteins. Although the demand for cetuximab for the treatment of cancer patients in clinics is increasing, the complicated techniques involved and its high cost limit its wide applications. Here, a new, cheaper form of cetuximab was generated for cancer gene therapy. This was achieved by cloning the full-length cetuximab antibody into two serotypes of adenoviral vectors, termed as AdC68-CTB and Hu5-CTB. In vivo studies showed that a single dose of AdC68-CTB or Hu5-CTB induced sustained cetuximab expression and dramatically suppressed tumor growth in NCI-H508– or DiFi-inoculated nude mice. In conclusion, gene therapy using adenovirus expressing full-length cetuximab could be a novel alternative method for the effective treatment of colorectal cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8596